Bio-Path completes cohort six of liposomal Grb-2 Phase I trial for blood cancers
In this cohort, three patients were evaluated and they showed that Liposomal Grb-2 is safe and well tolerated with the drug showing signs of anti-leukemia activity. The Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.